The American Gastroenterological Association released guidelines for hepatocellular carcinoma treatment Feb. 22.
Four recommendations from the AGA:
1. Systemic therapies are only recommended for those in stage C with preserved liver function. Atezolizumab and bevacizumab are recommended for first-line treatments rather than sorafenib.
2. Those in stage 0 and A who are also eligible for ablation, resection or transplant should receive curative surgery rather than systemic therapies.
3. Transarterial chemoembolization should be the first-line treatment for those in stage B.
4. Stage D patients should not receive systemic therapies. Instead, they should receive a transplant or best supportive care.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
